deltatrials

Janssen-Cilag G.m.b.H Clinical Trials

Sponsors / Janssen-Cilag G.m.b.H

ClinicalTrials.gov lists 16 trials for which Janssen-Cilag G.m.b.H is named as lead sponsor. The portfolio currently includes 1 recruiting studies, 2 active non-recruiting studies, and 8 completed studies. 4 trials in this portfolio were terminated or withdrawn before completion. The most common reasons cited for termination include slow or insufficient recruitment. Cumulative planned enrollment across all listed trials is 5,653 participants. These counts reflect the current state of the public ClinicalTrials.gov registry.

16
Total Trials
1
Recruiting
2
Other Active
8
Completed
4
Terminated / Withdrawn
5,653
Total Enrollment

Termination reasons: Other75% · Recruitment25%

Recent Terminations

  • NCT04252248 Phase PHASE1 Stopped Jun 2021
    Anogenital Cancer
    "Organizational reasons"
  • NCT00934635 Phase PHASE4 Stopped Dec 2009
    Schizophrenia
  • NCT01804673 Phase PHASE4 Stopped Sep 2008
    Postoperative Pain
    "The study was prematurely discontinued since study medication was no longer available."
  • NCT01902862 Phase PHASE2 Stopped Aug 2007
    Lymphoma, Follicular
    "Recruitment too slow"

Active Trials (2 total)

Top Conditions

Top Locations